Psychedelics Investing Optimi Health to Supply MDMA to MAPS Israel's Clinical Trial for Trauma-Related PTSD
Psychedelics Investing Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months
Psychedelics Investing NeuroKaire Enters into R&D Collaboration with Compass Pathways to Pioneer Precision Treatments for Depression
Psychedelics Investing Right Season Investments Engages MCS Market Communication Service to Provide Market Support
Psychedelics Investing Compass Pathways to Announce Third Quarter Financial Results on November 4, 2025
life science investing Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock
Psychedelics Investing Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto
Homerun Resources Inc. Announces Listing of Its Shares on Tradegate Exchange in Germany Increasing European and International Market Liquidity
